The WHO makes great sport of taking the pharmaceutical industry to task for its inability to provide everyone in the developing world with the drugs they need. This so-called market failure is being used at negotiations in Geneva this month to bring research and patents under official control, managed by the WHO.
But the WHO has trouble managing itself. Before it pushes on with this agenda, it should make sure it has strong evidence.
In fact, though, it lacks evidence for this -- and many more of its global recommendations.
In the May issue of The Lancet, researchers found that "WHO guidelines do not seem to be closely followed when [the] WHO develops recommendations for member states."
The editor of The Lancet told reporters that this "is a pretty seismic event ... it undermines the very purpose of [the] WHO."
The most sensitive indicator of broad health trends is the infant mortality rate. In September, UNICEF released new data showing that "the global rate for the under-five population fell from 20 million annually in 1960 to 9.7 million in 2006."
But The Lancet published in the same month an article showing "disappointing results in the reduction of child mortality worldwide" and concluded by asking "why should journals trust the research such agencies produce and why should anyone trust their health policies and initiatives?"
The WHO's new Draft Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (IGWG) aims to further weaken intellectual property and bring research and development under the control of governments and international bodies. It claims there are too few drugs for the "neglected" tropical diseases found in poor countries and that drug prices -- and the international patent system -- prevent the poor from getting what medicines do exist.
In fact, three of these "neglected" diseases are AIDS, tuberculosis and malaria. Since 2004, donors have spent an enormous US$41.8 billion on them.
Six tropical diseases, often considered "neglected," account for 0.3 percent of all global deaths -- and all of these diseases have multi-million-dollar research projects underway.
As for the alleged barrier of drug prices, numerous studies -- including the WHO's -- show that the most important barrier to the poor getting medicines is lack of medical staff and infrastructure to administer the drugs. And the biggest factor in the actual price paid by patients is local regulation, taxes and tariffs in poor countries.
So there is plenty of evidence, but the WHO is ignoring it.
Indeed, past evidence, from telephone monopolies to Chinese central planning, shows that nationalizing any business stifles innovation and, in the case of drugs, would hinder future efforts to create drugs for the poorest countries. This is particularly threatening, as drug-resistant strains of HIV/AIDS, malaria and tuberculosis become more prevalent in these regions.
The WHO wants to bring drug development under official control, replacing the commercial research and development, underpinned by intellectual property rights, that has proved so successful in so many fields. Not only will this treaty undermine innovation, it is supported by false premises and flies in the face of real evidence.
Taiwan, denied participation in the WHO, knows all too well how politics trumps evidence or sense in international organizations. Member states need to knock this treaty on the head at this month's meeting before the WHO does lasting damage to global health.
Jeremiah Norris is director of the Center for Science in Public Policy at the Hudson Institute, a policy think tank in Washington.
Weeks into the craze, nobody quite knows what to make of the OpenClaw mania sweeping China, marked by viral photos of retirees lining up for installation events and users gathering in red claw hats. The queues and cosplay inspired by the “raising a lobster” trend make for irresistible China clickbait. However, the West is fixating on the least important part of the story. As a consumer craze, OpenClaw — the AI agent designed to do tasks on a user’s behalf — would likely burn out. Without some developer background, it is too glitchy and technically awkward for true mainstream adoption,
Out of 64 participating universities in this year’s Stars Program — through which schools directly recommend their top students to universities for admission — only 19 filled their admissions quotas. There were 922 vacancies, down more than 200 from last year; top universities had 37 unfilled places, 40 fewer than last year. The original purpose of the Stars Program was to expand admissions to a wider range of students. However, certain departments at elite universities that failed to meet their admissions quotas are not improving. Vacancies at top universities are linked to students’ program preferences on their applications, but inappropriate admission
On Monday, a group of bipartisan US senators arrived in Taiwan to support the nation’s special defense bill to counter Chinese threats. At the same time, Beijing announced that Chinese President Xi Jinping (習近平) had invited Chinese Nationalist Party (KMT) Chairwoman Cheng Li-wun (鄭麗文) to visit China, a move to make the KMT a pawn in its proxy warfare against Taiwan and the US. Since her inauguration as KMT chair last year, Cheng, widely seen as a pro-China figure, has made no secret of her desire to interact with the Chinese Communist Party (CCP) and meet with Xi, naming it a
Taiwan-South Korea relations face a critical test, as a deadline forces both sides to confront a long-simmering issue. Taipei has requested that Seoul correct its classification of Taiwan in South Korea’s e-arrival system, where it has been labeled as “China (Taiwan)” since Feb. 24 last year. The Ministry of Foreign Affairs set today as a clear deadline for revision, warning that failure to act would trigger reciprocal measures beginning tomorrow. Taipei has already signaled its willingness to respond. Beginning on March 1, the government changed the designation of South Koreans on the alien resident certificates from the “Republic of Korea” to “South
RSS